Ikeda Jun-ichiro, Oda Tomofumi, Inoue Masayoshi, Uekita Takamasa, Sakai Ryuichi, Okumura Meinoshin, Aozasa Katsuyuki, Morii Eiichi
Department of Pathology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Cancer Sci. 2009 Mar;100(3):429-33. doi: 10.1111/j.1349-7006.2008.01066.x. Epub 2008 Dec 11.
CUB domain containing protein (CDCP1), a transmembrane protein with intracellular tyrosine residues which are phosphorylated upon activation, is supposed to be engaged in proliferative activities and resistance to apoptosis of cancer cells. Expression level of CDCP1 was examined in lung adenocarcinoma, and its clinical implications were evaluated. CDCP1 expression was immunohistochemically examined in lung adenocarcinoma from 200 patients. Staining intensity of cancer cells was categorized as low and high in cases with tumor cells showing no or weak and strong membrane staining, respectively. MIB-1 labeling index was also examined. There were 113 males and 87 females with median age of 63 years. Stage of disease was stage I in 144 cases (72.0%), II in 19 (9.5%), and III in 37 (18.5%). Sixty of 200 cases (30.0%) were categorized as CDCP1-high, and the remaining as CDCP1-low. Significant positive correlation was observed between CDCP1-high expression and relapse rate (P < 0.0001), poor prognosis (P < 0.0001), MIB-1 labeling index (P < 0.0001), and occurrence of lymph node metastasis (P = 0.0086). There was a statistically significant difference in disease-free survival (DFS) (P < 0.0001) and overall survival (OS) rates (P < 0.0001) between patients with CDCP1-high and CDCP1-low tumors. Univariate analysis showed that lymph node status, tumor stage, and CDCP1 expression were significant factors for both OS and DFS. Multivariate analysis revealed that only CDCP1 expression was an independent prognostic factor for both OS and DFS. CDCP1 expression level is a useful marker for prediction of patients with lung adenocarcinoma
含CUB结构域蛋白（CDCP1）是一种跨膜蛋白，其胞内酪氨酸残基在激活后会发生磷酸化，被认为参与癌细胞的增殖活动和抗凋亡过程。检测了肺腺癌中CDCP1的表达水平，并评估了其临床意义。对200例肺腺癌患者进行了CDCP1表达的免疫组化检测。肿瘤细胞的染色强度根据肿瘤细胞无膜染色或弱膜染色、强膜染色分别分为低和高。还检测了MIB-1标记指数。患者中男性113例，女性87例，中位年龄63岁。疾病分期为I期144例（72.0%），II期19例（9.5%），III期37例（18.5%）。200例患者中有60例（30.0%）为CDCP1高表达，其余为CDCP1低表达。观察到CDCP1高表达与复发率（P < 0.0001）、预后不良（P < 0.0001）、MIB-1标记指数（P < 0.0001）和淋巴结转移发生率（P = 0.0086）之间存在显著正相关。CDCP1高表达和低表达肿瘤患者的无病生存期（DFS）（P < 0.0001）和总生存期（OS）率（P < 0.0001）存在统计学显著差异。单因素分析显示，淋巴结状态、肿瘤分期和CDCP1表达是OS和DFS的显著因素。多因素分析显示，只有CDCP1表达是OS和DFS的独立预后因素。CDCP1表达水平是预测肺腺癌患者的有用标志物
